TSTanvi Sarwal

Tanvi Sarwal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tanvi Sarwal has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • [177Lu]Lutetium-hydroxyapatite radiosynovectomy in refractory chronic inflammatory arthritis of the knee joint

    by Tanvi Sarwal, Rajesh Kumar, Sameer Taywade, Abhay Elhence, Maya Gopalakrishnan, Siyaram Didel, Ravi Gaur

    To determine the efficacy of [177Lu]Lu-Hydroxyapatite radiosynovectomy (RSV) in patients with refractory chronic inflammatory arthritis of the knee joint. Overall, 24 knees in 22 patients with refractory chronic inflammatory arthritis were enrolled in this prospective study. All patients were assessed clinically for pain, tenderness, range of motion, analgesic intake, Oxford Knee Score, and scintigraphically based on blood pool activity on three-phase bone scan. Various scores were assigned to clinical these parameters. RSV of the knee joint was done using intra-articular injection of [177Lu]Lu-Hydroxyapatite. Patients were assessed clinically at 1 and 3 months, and scintigraphically at 3 months using blood pool index on three-phase bone scan. Patients were categorised as responders and non-responders on the basis of change in percentage of cumulative scores. Out of 24 knees, 18 knees were responders and 6 knees were non-responders at 3 months. There was a significant improvement in clinical scores at 1 month post-RSV, which persisted at 3 months post-RSV (p < 0.05). However, the change in blood pool activity on three-phase bone scan was not significant. Reported adverse effects were mild and not significant. This study confirmed the safety and efficacy of [177Lu]Lu-Hydroxyapatite radiosynovectomy for patients with chronic inflammatory knee joint arthritis refractory to conventional medical treatment.


  • Open Access

    Lutetium-177 hydroxyapatite radiosynovectomy in refractory chronic inflammatory arthritis of the knee joint

    by Tanvi Sarwal, Rajesh Kumar, Sameer Taywade, Maya Gopalakrishnan, Abhay Elhence, Siyaram Didel, Ravi Gaur

    Objective: To determine the efficacy of 177 Lutetium hydroxyapatite radiosynovectomy (RSV) in patients with refractory chronic inflammatory arthritis of the knee joint. Materials and Methods: Overall, 24 knees in 22 patients with refractory chronic inflammatory arthritis were enrolled in this prospective study. All patients were assessed clinically for pain, tenderness, range of motion, analgesic intake, Oxford knee score and blood pool activity on three phase bone scan. Various scores were assigned to clinical these parameters. RSV of the knee joint was done using intra-articular injection of 177 Lutetium hydroxyapatite. Patients were assessed clinically at 1 and 3 months, and scintigraphically at 3 months using blood pool index on three phase bone scan. Patients were categorised as responders and non-responders on the basis of change in percentage of cumulative scores. Results: Out of 24 knees, 18 knees were responders and 6 knees were non-responders at 3 months. There was a significant improvement in clinical scores at 1 month post RSV, which persisted at 3 months post RSV (p < 0.05). However, the change in blood pool activity on three phase bone scan was not significant. Reported adverse effects were mild and not significant. Conclusion: This study confirmed the safety and efficacy of 177 Lutetium hydroxyapatite radiosynovectomy for patients with chronic inflammatory knee joint arthritis refractory to conventional medical treatment.

  • Open Access

    Discerning the Role and Appropriate Timing of Furosemide Administration in 99mTc methylene diphosphonate Bone Scintigraphy: A randomized controlled trial.

    by Tanvi Sarwal, Praveen Gururani, Satyawati Deswal, Jiwan Paudel

    Bone scintigraphy is a highly sensitive nuclear medicine imaging technique used to detect various pathologies of bone. Usually, whole body planar images are acquired at 2.5 to 3 hours after 99mTc MDP injection in order to obtain a high bone to soft tissue activity ratio. However, in certian categories of patients, such as the obese, even after 3 hours, there is persistent high soft tissue activity, resulting in poor image quality. Furosemide is a loop diuretic which increases renal excretion of the radiotracer, 99mTc MDP, from the soft tissues. Theoritically, it would lead to higher target to backgroud ratio, and hence superior image quality. Thus, we investigated the effect of additon of furosemide on the image quality of bone scintigraphy with 99mTc MDP.

  • Interesting Presentation of Mycosis Fungoides in Staging on F-18 FDG PET/CT

    by Deepanksha Datta, Tanvi Sarwal, Rajesh Kumar, Sandeep Bairwa, Vinay N. Gowda, Aasma Nalwa

    Mycosis fungoides is the major form of primary cutaneous T cell lymphoma. Its staging is based on the percentage of body surface involvement and biopsy-proven extra cutaneous nodal or visceral involvement. Literature shows F-18 FDG accumulation in disease-involved nodes and viscera with non-specific uptake due to co-existing inflammation limits its specificity. We report an interesting case of mycosis fungoides with bilateral upper limb edema and share its findings on F-18 FDG PET/CT.

  • Open Access

    Healthcare providers perceptions regarding the presence of Birth Companion during childbirth at a tertiary care hospital in India

    by Tanvi Sarwal, Yamini Sarwal, Shakun Tyagi, Rakesh Sarwal

    Background: Despite an increase in institutional births and a fall in maternal mortality, the satisfaction of women with their birthing experience in public health institutions is low. Birth Companion (BC) is an important part of the Labour Room Quality Improvement Initiative introduced by the Government of India in 2017. Despite mandates, its implementation has been unsatisfactory. Little is known about the perception of healthcare providers about BC. Methods: We conducted a facility-based, cross-sectional quantitative study with doctors and nurses in a tertiary care hospital in Delhi, India to gauge their awareness, perception and knowledge about BC. Following universal total population sampling, the participants were administered a questionnaire, which was completed by 96 of 115 serving doctors (response rate of 83%), and 55 of 105 serving nurses (response rate of 52%). Results: Most (93%) healthcare providers were aware of the concept of BC, WHO’s recommendation (83%) and Government’s instructions (68%) on BC during labour. A woman’s mother was the BC of choice (70%) closely followed by her husband (69%). Ninety-five percent of providers agreed that the presence of a BC during labour will be beneficial, in providing emotional support, boosting the woman’s confidence, providing comfort measures, helping in the early initiation of breastfeeding, reducing post-partum depression, humanizing labour, reducing the need for analgesia and increasing chances of spontaneous vaginal births. Yet, support for the introduction of BC in their hospital was low due to institutional barriers like overcrowding, lack of privacy, hospital policy, risk of infection; privacy issues and costs. Conclusions: Widespread adoption of the concept of BC would require, besides directives, a buy-in by the providers, and action on their suggestions. These include greater funding for hospitals, creating physical partitions to ensure privacy, sensitization and training of health providers and BC, incentivizing hospitals and birthing women, formulation of guidelines on BC, standards setting and a change in institutional culture.


  • Prioritizing pregnant women for COVID‐19 vaccination

    by Yamini Sarwal, Tanvi Sarwal, Rakesh Sarwal

    Despite emerging evidence on safety and efficacy, most countries do not offer COVID‐19 vaccines to pregnant women even though they are at higher risk of complications from COVID‐19. We performed a web search of COVID‐19 vaccination policies for pregnant women under two categories: countries bearing a high burden of COVID‐19 cases and countries with a high burden of maternal and under‐five mortality. Of the top 20 countries affected by COVID‐19, 11 allow vaccination of pregnant women, of which two have deemed it safe to vaccinate pregnant women as a high‐risk group. In contrast, only five of the 20 countries with high under‐five mortality and maternal mortality allow vaccination of pregnant women and none of these countries has included them as part of a high‐risk group that should be vaccinated. India and Indonesia, with one‐fifth of the world's population, fall under both categories but do not include pregnant women as a priority group for COVID‐19 vaccination. To prevent COVID‐19 from further aggravating the already heavy burden of maternal and under‐five mortality, there is a strong case for including pregnant women as a high‐priority group for COVID‐19 vaccination. We recommend including COVID‐19 vaccination in routine antenatal care in all countries, particularly India and Indonesia in view of their high dual burden.


  • Open Access

    Opinion of Health Care Providers on Birth Companions in Obstetrics Department of a Tertiary Care Hospital in North India

    by Tanvi Sarwal, Yamini Sarwal, Shakun Tyagi, Rakesh Sarwal

    Background Despite impressive improvements in institutional births and a fall in maternal mortality, satisfaction of women with birthing experience in public health institutions is low (68%). Birth Companion is an important part of the Labour room Quality Improvement (LaQshya) programme introduced by the Government of India in 2017. Despite mandates, implementation of the concept has been unsatisfactory (9%), even though the importance of Birth Companion has increased due to enhanced risk posed by COVID-19. Little is known about awareness among health care providers on Birth Companions, perceived barriers or their suggestions. Methods We canvassed a 15-question instrument using ordinal scales on 151 health care providers comprising consultants, post graduates, residents, and nurses (response rate 69%) in the department of Obstetrics & Gynecology, Lok Nayak Hospital, Delhi, India to gauge their awareness and opinions about Birth Companions. Results Most health care providers across all categories were aware of the concept (93%), World Health Organization’s recommendation (83%) and Government’s instructions for its hospitals (68%) that every woman should be accompanied by a Birth Companion of her choice during labour. Birth Companions of choice suggested by them were the mother (70%), husband (69%). sister (46%) or nurse (43%). Most health care providers agreed that a Birth Companion should wear clean clothes (95%), be free from any communicable disease (91%), stay with the pregnant woman throughout the process of labour (74%) and should have herself gone though labour (42%). Almost all providers (95%) agreed that the presence of a Birth Companion during labour will be beneficial, as they would provide emotional support (99%), boost the woman’s confidence (98%), provide comfort measures like massage (95%), early initiation of breastfeeding (93%), reduce post-partum depression (91%), humanize labour (83%), reduce need for analgesia (70%) and increase spontaneous vaginal births (69%). Yet support for its introduction in their hospital was low (59%). Staff nurses had reservations (62%) with only 40% of those who believed Birth Companion to be beneficial approving of its introduction in their hospital. Over-crowding in labour room and privacy concerns for other women were identified as key barriers. Conclusion Even though most health care providers were aware of and convinced of multiple benefits of Birth Companion during labour, lack of adequate infrastructure in the labour room prevented them from supporting its introduction. Government should provide adequate funding to upgrade labour rooms in a way that provides privacy to the delivering women and frame guidelines and train Birth Companions to perform their role appropriately.


  • Open Access

    Prioritizing Pregnant Women for COVID-19 Vaccination

    by Yamini Sarwal, Tanvi Sarwal, Rakesh Sarwal

    Even though evidence for safety and efficacy is emerging, most countries do not offer vaccination to pregnant women, despite they being at higher risk of complications from COVID-19. We did a web search on policies for COVID-19 vaccination of pregnant women in two sets of countries – those bearing a high burden of COVID-19 cases, and a second set with a high burden of maternal andunder five mortality globally. Of the top 20 COVID-19 affected countries, nine allow vaccination of pregnant women, of which two preferentially vaccinate pregnant women. In contrast, four of the 20 high under-five mortality countries allow vaccination of pregnant women, while none has included them in the preferential group. India and Indonesia with one fifth of world’s population fall in both the groups, but do not include pregnant women for COVID-19 vaccination.For COVID-19 not to further aggravate the already heavy burden of maternal and under five mortality, there is a strong case for inclusion of pregnant women as a high priority group for COVID-19 vaccination. We recommend including COVID-19 vaccination in the routine protocol for antenatal care in all countries, particularly India and Indonesia in view of their high dual burden.